Nov 8 2010
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today hosted its Respiratory Opportunity Meeting for the financial community in New York, featuring in-depth presentations on Teva's current and future respiratory growth strategy. Teva's expertise in the respiratory marketplace, combined with the strength of its unique product pipeline, is expected to contribute approximately $2.4 billion to the Company's overall 2015 targets of $31 billion. Teva intends to file ten products, six of which are new brands, for approval in the U.S. and Europe by 2015, targeting approximately $25 billion in brand value, including new combination products
“One of the key pillars of Teva's long term strategy is the expansion of our branded business—and our respiratory franchise will play an important role in this growth”
"One of the key pillars of Teva's long term strategy is the expansion of our branded business—and our respiratory franchise will play an important role in this growth," said Shlomo Yanai, Teva's President and Chief Executive Officer. "Over the next five years, and beyond, Teva's unique product portfolio and robust pipeline will enable us to significantly expand our presence in the global respiratory market. We are very enthusiastic about the many opportunities ahead for our respiratory business."
Teva is currently one of the top five players in the global respiratory market which, according to IMS, is valued at more than $30 billion. Since the acquisition of IVAX Pharmaceuticals in 2006, Teva's global respiratory product sales have nearly tripled; by the end of 2010, annual respiratory sales are projected to reach $1 billion.
An archive of the webcast and presentation are available on Teva's website at http://www.tevapharm.com/financial/
Source:
Teva Pharmaceutical Industries Ltd.
Higher vitamin D levels tied to fewer hospitalization for respiratory tract infections